A Phase 2 interventional study of pemetrexed in Osteosarcoma, Medulloblastoma and Sarcoma, Ewing's, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged Up to 22 Years. Per ClinicalTrials.gov, last updated 2011-02-25.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 167 studies in Sarcoma, Ewing with a site in United States — 39 open to participants now, 61 under way, 1 of them phase 3. Sarcoma, Ewing · United States.
Among the 167 studies in Sarcoma, Ewing with a site in United States, this one is the 40th largest by enrollment of the 155 interventional ones that give a count, is one of 5 that started in 2007, is one of 47 in phase 2, and was the 21st registered.
250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.
Browse Sarcoma, Ewing studies →39 of the 167 studies in Sarcoma, Ewing with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Milton S. Hershey Medical Center · Sites in United States
Ages 0–50
Milton S. Hershey Medical Center · Sites in United States
Ages up to 26
University of California, Irvine · Sites in United States
Ages 18+
Amgen · Sites in United States, Australia
Ages 2+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger; 49 take children under 18; 2 take healthy volunteers.
This study: Up to 22 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
167 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 91 · Phase 2 78 · Phase 3 5
First in 1986; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 36 across 204 interventional studies indexed under Sarcoma, Ewing.
Median enrollment 30 across the 155 interventional studies, 257 across the 10 observational. Of the 95 that completed or were terminated, 45 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 167 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Sarcoma, Ewing — fewer than ten, so there is no comparison to draw.
17 of the studies in Sarcoma, Ewing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04337177Valent Technologies, LLCFlavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | 2026-12 |
| NCT02508038University of Wisconsin, MadisonAlpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | 2026-12 |
| NCT02013336South Plains Oncology ConsortiumPhase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | 2026-12 |
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT04308330New York Medical CollegeVorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 167 studies in Sarcoma, Ewing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET or non-brain stem high-grade glioma.
250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.
This study's enrollment of 72 is above the median of 36 across 204 interventional studies indexed under Sarcoma, Ewing.
Browse Sarcoma, Ewing studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Sarcoma, Ewing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteosarcoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed
1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
Also known as: LY 231514, Alimta
Percentage of Participants With Overall Tumor Response (Response Rate)
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response = disappearance of all target lesions. Partial Response = 30% decrease in sum of longest diameter of target lesions. Response rate (percent \[%\])= (number of participants with complete response (CR) or partial response (PR) in stratum/number of participants in stratum)\*100.
Time frame: baseline to measured progressive disease (up to 1 year)
Number of Patients With Adverse Events, Discontinuations, or Deaths Possibly Due to Study Drug
AdEERS= Adverse Event Expedited Reporting System; AE = adverse event. Patients may be counted in more than 1 category. Includes events that were considered possibly related to study drug (PRSD) as judged by the investigator.
Time frame: every cycle (up to 2 years and 7 months)
Pharmacogenomics - Measure the Response of Genes Related to Toxicity
The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here. Results of this optional research may be reported in the future by the Children's Oncology Group in the peer-reviewed literature.
Time frame: baseline
| Milestone | Osteosarcoma | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | Rhabdomyosarcoma | Neuroblastoma (Measureable Disease) | Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | Ependymoma | Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | Non-Brainstem High-Grade Glioma |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 11 | 9 | 5 | 6 | 10 | 11 | 10 |
| Completed | 10 | 7 | 7 | 5 | 5 | 10 | 7 | 9 |
| Not completed | 0 | 4 | 2 | 0 | 1 | 0 | 4 | 1 |
| Withdrew: Physician decision | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Toxicity requiring removal from study | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response = disappearance of all target lesions. Partial Response = 30% decrease in sum of longest diameter of target lesions. Response rate (percent \[%\])= (number of participants with complete response (CR) or partial response (PR) in stratum/number of participants in stratum)\*100.
| Percentage of Participants | Osteosarcoma | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | Rhabdomyosarcoma | Neuroblastoma (Measureable Disease) | Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | Ependymoma | Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | Non-Brainstem High-Grade Glioma |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Overall Tumor Response (Response Rate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AdEERS= Adverse Event Expedited Reporting System; AE = adverse event. Patients may be counted in more than 1 category. Includes events that were considered possibly related to study drug (PRSD) as judged by the investigator.
| Participants | Osteosarcoma | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | Rhabdomyosarcoma | Neuroblastoma (Measureable Disease) | Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | Ependymoma | Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | Non-Brainstem High-Grade Glioma |
|---|---|---|---|---|---|---|---|---|
| >=1 AdEERs possibly related to study drug | 3 | 2 | 0 | 2 | 3 | 2 | 2 | 2 |
| Discontinued due to AE possibly related to drug | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 |
| Died on therapy possibly related to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Died within 31 days of last dose of drug PRSD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The pharmacogenomics outcomes examining the correlation between the presence of the methylene tetrahydrofolate reductase gene and the presence of a polymorphism in the thymidylate synthase (TS) gene and/or gene promoter and toxicity were optional and will not be reported here. Results of this optional research may be reported in the future by the Children's Oncology Group in the peer-reviewed literature.
No measurements were reported for this outcome.
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | 21/72 (29.2%) | 10/72 (13.9%) |
| Event | Pemetrexed |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 4/72 |
| Infection with normal ANC or Grade 1Blood and lymphatic system disorders | 4/72 |
| LeukocytesBlood and lymphatic system disorders | 3/72 |
| LymphopeniaBlood and lymphatic system disorders | 3/72 |
| Neutrophils/granulocytesBlood and lymphatic system disorders | 3/72 |
| Phosphate, serum-lowMetabolism and nutrition disorders | 3/72 |
| Death not associated with CTCAE termRespiratory, thoracic and mediastinal disorders | 3/72 |
| InfectionBlood and lymphatic system disorders | 2/72 |
| PlateletsBlood and lymphatic system disorders | 2/72 |
| NauseaGastrointestinal disorders | 2/72 |
| Event | Pemetrexed |
|---|---|
| Infection with normal ANC or Grade 1Blood and lymphatic system disorders | 2/72 |
| FeverGeneral disorders | 2/72 |
| SeizureNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/72 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/72 |
| Dermatology/Skin - OtherCardiac disorders | 1/72 |
| Pulmonary/Upper Respiratory - OtherCardiac disorders | 1/72 |
| Thrombosis/thrombus/embolismCardiac disorders | 1/72 |
| Sodium, serum-lowCongenital, familial and genetic disorders | 1/72 |
| DiarrheaGastrointestinal disorders | 1/72 |
| Hemorrhage, GI: RectumGastrointestinal disorders | 1/72 |
| Age Continuous(years) | Osteosarcoma | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | Rhabdomyosarcoma | Neuroblastoma (Measureable Disease) | Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | Ependymoma | Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | Non-Brainstem High-Grade Glioma | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 14.94 ± 4.28 | 18.24 ± 3.35 | 8.74 ± 4.96 | 6.23 ± 2.98 | 9.62 ± 5.38 | 8.42 ± 4.59 | 12.00 ± 7.13 | 12.75 ± 5.15 | 11.96 ± 5.97 |
| Sex: Female, Male(Participants) | Osteosarcoma | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | Rhabdomyosarcoma | Neuroblastoma (Measureable Disease) | Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | Ependymoma | Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | Non-Brainstem High-Grade Glioma | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 8 | 6 | 1 | 1 | 3 | 4 | 5 | 32 |
| Male | 6 | 3 | 3 | 4 | 5 | 7 | 7 | 5 | 40 |
| Race/Ethnicity, Customized(Participants) | Osteosarcoma | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | Rhabdomyosarcoma | Neuroblastoma (Measureable Disease) | Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | Ependymoma | Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | Non-Brainstem High-Grade Glioma | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Asian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Black or African American | 4 | 0 | 0 | 2 | 1 | 1 | 3 | 3 | 14 |
| White | 4 | 8 | 7 | 2 | 4 | 9 | 8 | 6 | 48 |
| Other | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 3 |
| Unknown | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 3 |
| Region of Enrollment(participants) | Osteosarcoma | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | Rhabdomyosarcoma | Neuroblastoma (Measureable Disease) | Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | Ependymoma | Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | Non-Brainstem High-Grade Glioma | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 7 | 7 | 8 | 5 | 5 | 9 | 10 | 10 | 61 |
| Canada | 3 | 4 | 1 | 0 | 1 | 1 | 1 | 0 | 11 |
| Karnofsky Performance Score(Participants) | Osteosarcoma | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | Rhabdomyosarcoma | Neuroblastoma (Measureable Disease) | Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | Ependymoma | Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | Non-Brainstem High-Grade Glioma | Total |
|---|---|---|---|---|---|---|---|---|---|
| 100 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 3 |
| 90 | 3 | 3 | 0 | 0 | 1 | 0 | 1 | 1 | 9 |
| 80 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| 70 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| 50 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Missing | 6 | 4 | 9 | 5 | 5 | 9 | 8 | 8 | 54 |
| Lansky Play Score(Participants) | Osteosarcoma | Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumors | Rhabdomyosarcoma | Neuroblastoma (Measureable Disease) | Neuroblastoma (Metaiodobenzylguanidine Positive Evaluable) | Ependymoma | Medulloblastoma/Supratentorial Primitive Neuroectodermal Tumor | Non-Brainstem High-Grade Glioma | Total |
|---|---|---|---|---|---|---|---|---|---|
| 100 | 1 | 1 | 3 | 4 | 2 | 2 | 2 | 3 | 18 |
| 90 | 1 | 3 | 3 | 1 | 1 | 2 | 3 | 4 | 18 |
| 80 | 2 | 0 | 2 | 0 | 2 | 3 | 2 | 0 | 11 |
| 70 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| 60 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 4 |
| 50 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Missing | 4 | 7 | 0 | 0 | 1 | 1 | 3 | 2 | 18 |
The record gives a start of Sep 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed